Ou Jiang
Overview
Explore the profile of Ou Jiang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
362
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhao M, Hu X, Zhuang P, Zeng A, Yu Y, Chen Z, et al.
J Bone Oncol
. 2025 Feb;
51:100661.
PMID: 39995685
Introduction: Denosumab (Xgeva®) is a standard treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases (BM). This trial was designed to assess the equivalence of LY01011...
2.
He R, Lai J, Jiang O, Li J
J Gastrointest Surg
. 2024 Dec;
29(2):101935.
PMID: 39701515
Background: Challenges persist in the management of appendicitis in children, but its incidence and temporal trends have been reported in only a few developed countries. This study aimed to comprehensively...
3.
Dong B, Chen L, Pang Q, Jiang O, Ge H, Cheng Y, et al.
Transl Lung Cancer Res
. 2024 Nov;
13(10):2828-2837.
PMID: 39507039
Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of non-small cell lung cancer (NSCLC). TQB2450 (benmelstobart) is a novel humanized immunoglobulin G1 monoclonal antibody against programmed death-ligand 1 (PD-L1)....
4.
Cheng Y, Pan Z, Wu L, Zhu B, Yu Y, Zang K, et al.
Adv Ther
. 2024 Sep;
41(11):4032-4048.
PMID: 39230871
Introduction: SCT510 is a biosimilar to bevacizumab (Avastin) reference product (RP) that is approved for various metastatic cancers. In this study, we aimed to demonstrate the equivalence of SCT510 and...
5.
Zuo J, Duan W, Zhao M, Chen Z, Lin J, Shi H, et al.
Cancer Commun (Lond)
. 2024 Jul;
44(9):1042-1046.
PMID: 39044367
No abstract available.
6.
Cheng Y, Chen J, Zhang W, Xie C, Hu Q, Zhou N, et al.
Nat Med
. 2024 Jul;
30(10):2967-2976.
PMID: 38992123
Immunochemotherapy is the first-line standard for extensive-stage small-cell lung cancer (ES-SCLC). Combining the regimen with anti-angiogenesis may improve efficacy. ETER701 was a multicenter, double-blind, randomized, placebo-controlled phase 3 trial that...
7.
Cui R, Li Y, Yu X, Wei C, Jiang O
PLoS One
. 2024 Jun;
19(6):e0304941.
PMID: 38865375
Background: The recent usage of immunotherapy combined with chemoradiotherapy has improved survival in advanced non-small cell lung cancer (NSCLC) patients. However, determining the most effective therapy combination remains a topic...
8.
Zheng Y, Zhu J, Xiong J, Jiang O, Wang H, Xie Y, et al.
Cancer
. 2024 Feb;
130(12):2180-2190.
PMID: 38412283
Background: Penpulimab, a new-generation antiprogrammed cell death-1 immunoglobulin G1 monoclonal antibody, was engineered to optimize receptor occupancy and eliminate fragment crystallizable γ-mediated effector function. In this multicenter, phase 1b/2, multicohort...
9.
Yu X, Wei C, Cui R, Jiang O
Int J Clin Exp Pathol
. 2023 Dec;
16(11):321-331.
PMID: 38059174
Lenvatinib, an FDA-approved first-line oral multi-kinase inhibitor for advanced hepatocellular carcinoma (aHCC), has demonstrated promise for treatment. Nevertheless, findings from the Leap-002 study suggest that the addition of anti-vascular drugs...
10.
Li X, Jiang O, Wang S
Int J Oral Sci
. 2023 Dec;
15(1):52.
PMID: 38040705
Many tissues and organ systems have intrinsic regeneration capabilities that are largely driven and maintained by tissue-resident stem cell populations. In recent years, growing evidence has demonstrated that cellular metabolic...